Clinical Trials Logo
  1. Home
  2. Idiopathic Gastroparesis
  3. NCT01625923

A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis

Idiopathic Gastroparesis Clinical Trial

Official title:
A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis

Clinical Trial Summary

Gastroparesis is a disorder characterized by impaired gastric emptying in the absence of obstruction in the proximal GI tract. It is a common condition affecting up to 5 million persons in the United States alone. Despite this, metoclopramide is currently the only FDA approved medication for the treatment of gastroparesis. However, the evidence supporting metoclopramide in gastroparesis is fairly weak and was recently issued a black box warning because of potential irreversible side effects. There is clearly an urgent need for newer therapeutic options with better efficacy and tolerability. Olanzapine is a second generation anti-psychotic that is currently FDA approved for the treatment of schizophrenia and bipolar disorder. Because of actions at several receptors throughout the body, including dopamine and serotonin receptors, Olanzapine may provide anti-nausea and pro-motility effects in the stomach. Long-term use of olanzapine may also increase plasma levels of ghrelin. Ghrelin is a hormone produced by the gut that stimulates appetite and has also been shown to have beneficial effects on gastroparesis. The investigators hypothesize that olanzapine will be effective and safe in controlling symptoms as well as stimulate appetite and weight gain in gastroparesis. The investigators also hypothesize that olanzapine will stimulate gastric motility. Finally, the investigators hypothesize that olanzapine will modulate the secretion of ghrelin in gastroparesis. This pilot study may provide further information on the efficacy and safety of olanzapine in gastroparesis which could be utilized in a larger randomized, prospective study in the future.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01625923
Study type Interventional
Source University of Michigan
Contact
Status Terminated
Phase N/A
Start date January 2013
Completion date June 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02232334 - Effects of Global Osteopathic Manual Treatments in Patients With Idiopathic Gastroparesis N/A
Completed NCT03544229 - A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis Phase 2
Completed NCT02732821 - G-POEM for Treatment of Refractory Gastroparesis
Completed NCT01916460 - Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients N/A
Completed NCT01696747 - Gastroparesis Registry 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT03680859 - Gastroparesis Registry 3
Completed NCT00765895 - Nortriptyline for Idiopathic Gastroparesis Phase 3
Completed NCT03281577 - Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants Phase 2
Enrolling by invitation NCT03176927 - Biomagnetic Characterization of Gastric Dysrhythmias III N/A
Recruiting NCT04028492 - Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis Phase 3
Completed NCT04303195 - A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis Phase 2